CRB’s Horizons: Life Sciences report explores how the industry is adapting to chaos, with companies accelerating despite uncertainty. Survey data shows tariff pressures haven’t deterred investment plans, with large pharmaceutical firms leading new capacity commitments. The report highlights industry shifts in global strategies, process innovation, and workforce engagement to navigate trade turbulence and regulatory changes.

Read more at GlobeNewswire: New CRB Horizons Report Shows